Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Verrucarin A is a potent Type D macrocyclic trichothecene mycotoxin primarily produced by fungi such as *Albifimbria verrucaria* (formerly *Myrothecium verrucaria*). It acts as a potent inhibitor of protein synthesis by binding to the A-site of the 60S ribosomal subunit in eukaryotes, thereby triggering a ribotoxic stress response. Beyond its role as a toxin, verrucarin A has been investigated for its significant anticancer properties, demonstrating the ability to induce apoptosis and inhibit prosurvival signaling pathways such as Akt/NF-κB/mTOR. It also functions as an inhibitor of steroid receptor coactivators (SRC-1, SRC-2, and SRC-3). Due to its high systemic toxicity, recent research has focused on targeted delivery systems, including antibody-directed extracellular vesicles (EVs) and folate-receptor-targeted conjugates, to treat glioblastoma, triple-negative breast cancer, neuroendocrine tumors, and inflammatory disorders. Additionally, it exhibits antifungal, antimalarial, and nematicidal activities.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on verrucarin A.